Udo  Rudloff, M.D., Ph.D.
Udo Rudloff, M.D., Ph.D.
Investigator
Head, Gastrointestinal Oncology Section

Center for Cancer Research
National Cancer Institute

Building 10 - Hatfield CRC, Room 4-5950
Bethesda, MD 20892
301-496-3098

Dr. Rudloff’s laboratory is working on preclinical drug development in pancreas cancer. His recent work identified novel mechanisms and genes involved in resistance to MAPK pathway inhibition, novel biomarkers predicting response to MEK and PI3K/mTOR inhibition, or an immunomodulatory anti-IL10 peptide mediating tumor regression and prolongation of survival in a transgenic animal model of pancreas cancer. Combinational experiments with gemcitabine and a TGFbeta receptor II inhibitor in transgenic animal models have shown that intratumoral gemcitabine levels rise depending on the underlying genotype of the tumor upon blockade of TGFbeta signaling.

Dr. Rudloff’s clinical expertise in HBP and pancreatic surgery supports a number of clinical and translational research efforts in patients with complex GI cancers.

Areas of Expertise
1) preclinical drug development, 2) pancreas cancer, 3) MAPK pathway inhibition, 4) biomarkers predicting MAPK and PI3K/Akt pathway inhibition, 5) transgenic animal models of pancreas cancer, 6) drug delivery to pancreatic tumors in transgenic animal models

Dr. Rudloff's clinical interests lie in the management of complex cancers of the liver, biliary tree, and pancreas. His laboratory efforts focus on preclinical drug development for pancreatic cancer and other gastrointestinal (GI) malignancies using in vitro and in vivo models, and the design of personalized treatment strategies for the individual genotype of patients' tumors.

Scientific Focus Areas:
Cancer Biology, Clinical Research
Selected Recent Publications
  1. Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
    Hum. Gene Ther. [Epub ahead of print], 2014. [ Journal Article ]
  2. Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U.
    Ann. Surg. Oncol. 21: 2484-9, 2014. [ Journal Article ]
  3. Lau C, Killian KJ, Samuels Y, Rudloff U.
    Methods Mol. Biol. 1102: 461-80, 2014. [ Journal Article ]
  4. Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I.
    J Surg Oncol. 110: 275-84, 2014. [ Journal Article ]
  5. Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
    Ann. Surg. Oncol. 20: 555-61, 2013. [ Journal Article ]

Dr. Rudloff is an investigator and surgical oncologist at the Surgery Branch, National Cancer Institute, National Institutes of Health, in Bethesda, Maryland. Dr. Rudloff completed his M.D. at the University of Heidelberg, Germany. For his doctoral thesis at the German Cancer Research Institute, Heidelberg, he worked on gene regulation of rRNA transcription. He graduated from New York University in 2007 upon completion of his surgical residency training and pursued subspecialty training in surgical oncology by completing a 2-year surgical oncology fellowship at Memorial Sloan Kettering Center in New York City. He was appointed to the senior staff of the Surgery Branch/NCI in July 2009.

Name Position
Dandan Li Ph.D. Visiting Fellow
Anne Miermont-Eltejaye Ph.D. Postdoctoral Fellow (CRTA)
Holger Pflicke Ph.D. Postdoctoral Fellow (Visiting)
Yaroslav Teper Ph.D. Research Fellow
Carole C. Webb R.N. Research Nurse Specialist
Athina Zacharia Visiting Fellow

Summary

Dr. Rudloff’s laboratory is working on preclinical drug development in pancreas cancer. His recent work identified novel mechanisms and genes involved in resistance to MAPK pathway inhibition, novel biomarkers predicting response to MEK and PI3K/mTOR inhibition, or an immunomodulatory anti-IL10 peptide mediating tumor regression and prolongation of survival in a transgenic animal model of pancreas cancer. Combinational experiments with gemcitabine and a TGFbeta receptor II inhibitor in transgenic animal models have shown that intratumoral gemcitabine levels rise depending on the underlying genotype of the tumor upon blockade of TGFbeta signaling.

Dr. Rudloff’s clinical expertise in HBP and pancreatic surgery supports a number of clinical and translational research efforts in patients with complex GI cancers.

Areas of Expertise
1) preclinical drug development, 2) pancreas cancer, 3) MAPK pathway inhibition, 4) biomarkers predicting MAPK and PI3K/Akt pathway inhibition, 5) transgenic animal models of pancreas cancer, 6) drug delivery to pancreatic tumors in transgenic animal models

Research

Dr. Rudloff's clinical interests lie in the management of complex cancers of the liver, biliary tree, and pancreas. His laboratory efforts focus on preclinical drug development for pancreatic cancer and other gastrointestinal (GI) malignancies using in vitro and in vivo models, and the design of personalized treatment strategies for the individual genotype of patients' tumors.

Scientific Focus Areas:
Cancer Biology, Clinical Research

Publications

Selected Recent Publications
  1. Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
    Hum. Gene Ther. [Epub ahead of print], 2014. [ Journal Article ]
  2. Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U.
    Ann. Surg. Oncol. 21: 2484-9, 2014. [ Journal Article ]
  3. Lau C, Killian KJ, Samuels Y, Rudloff U.
    Methods Mol. Biol. 1102: 461-80, 2014. [ Journal Article ]
  4. Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I.
    J Surg Oncol. 110: 275-84, 2014. [ Journal Article ]
  5. Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
    Ann. Surg. Oncol. 20: 555-61, 2013. [ Journal Article ]

Biography

Dr. Rudloff is an investigator and surgical oncologist at the Surgery Branch, National Cancer Institute, National Institutes of Health, in Bethesda, Maryland. Dr. Rudloff completed his M.D. at the University of Heidelberg, Germany. For his doctoral thesis at the German Cancer Research Institute, Heidelberg, he worked on gene regulation of rRNA transcription. He graduated from New York University in 2007 upon completion of his surgical residency training and pursued subspecialty training in surgical oncology by completing a 2-year surgical oncology fellowship at Memorial Sloan Kettering Center in New York City. He was appointed to the senior staff of the Surgery Branch/NCI in July 2009.

Team

Name Position
Dandan Li Ph.D. Visiting Fellow
Anne Miermont-Eltejaye Ph.D. Postdoctoral Fellow (CRTA)
Holger Pflicke Ph.D. Postdoctoral Fellow (Visiting)
Yaroslav Teper Ph.D. Research Fellow
Carole C. Webb R.N. Research Nurse Specialist
Athina Zacharia Visiting Fellow